King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Molecules. 2022 Aug 8;27(15):5042. doi: 10.3390/molecules27155042.
Cancer cells change their glucose and glutamine (GLU) metabolism to obtain the energy required to continue growing. Glutaminase (GLS) plays a crucial role in promoting cell metabolism for cancer cell growth; targeting GLU metabolism by inhibiting GLS has attracted interest as a potential cancer management strategy. Herein, we employed a sequential screening of traditional Chinese medicine (TCM) database followed by drug-likeness and molecular dynamics simulations against the active site of GLS. We report 12 potent compounds after screening the TCM database against GLS, followed by a drug-likeness filter with Lipinski and Veber rule criteria. Among them, ZINC03978829 and ZINC32296657 were found to have higher binding energy (BE) values than the control compound 6-Diazo-5-Oxo-L-Norleucine, with BEs of -9.3 and -9.7 kcal/mol, respectively, compared to the BE of 6-Diazo-5-Oxo-L-Norleucine (-4.7 kcal/mol) with GLS. Molecular dynamics simulations were used to evaluate the results further, and a 100 ns MD simulation revealed that the hits form stable complexes with GLS and formed 2-5 hydrogen bond interactions. This study indicates that these hits might be employed as GLS inhibitors in the battle against cancer. However, more laboratory tests are a prerequisite to optimize them as GLS inhibitors.
癌细胞改变葡萄糖和谷氨酰胺(GLU)代谢以获取继续生长所需的能量。谷氨酰胺酶(GLS)在促进癌细胞生长的细胞代谢中起着至关重要的作用;通过抑制 GLS 靶向 GLU 代谢已作为一种潜在的癌症管理策略引起关注。在此,我们采用了传统中药(TCM)数据库的序贯筛选,然后针对 GLS 的活性位点进行药物相似性和分子动力学模拟。我们在针对 GLS 筛选 TCM 数据库后报告了 12 种有效化合物,然后通过 Lipinski 和 Veber 规则标准进行了药物相似性筛选。其中,ZINC03978829 和 ZINC32296657 与对照化合物 6-重氮-5-氧代-L-正亮氨酸相比,具有更高的结合能(BE)值,分别为-9.3 和-9.7 kcal/mol,而 6-重氮-5-氧代-L-正亮氨酸与 GLS 的 BE 为-4.7 kcal/mol。分子动力学模拟进一步评估了结果,100 ns MD 模拟表明这些命中化合物与 GLS 形成稳定的复合物,并形成 2-5 个氢键相互作用。这项研究表明,这些命中化合物可能被用作癌症治疗中的 GLS 抑制剂。然而,更多的实验室测试是将它们优化为 GLS 抑制剂的前提条件。